Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Sunitinib

Sunitinib 50 mg D1-D28 every 6 weeks

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Kyungpook National University Hospital

OTHER

lead

Asan Medical Center

OTHER

NCT01219751 - Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter